Elicera Therapeutics AB (DE:8E8)

FRANKFURT:8E8

8E8

Elicera Therapeutics AB

RESEARCH TOOLSreports

Elicera Therapeutics AB (8E8) Price & Analysis

0 Followers

8E8 Stock Chart & Stats

€0.47

€0.03(20.86%)

At close: Jan 08 4:00 PM EST

€0.47

€0.03(20.86%)

Day’s Range― - ―

52-Week Range€0.23 - €0.67

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€19.71M

Enterprise Value€132.32M

Total Cash (Recent Filing)€24.85M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.38

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding72,803,314

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

No Debt / Conservative LeverageZero reported debt provides durable financial flexibility for an R&D-stage biotech: it lowers insolvency risk, preserves capacity to raise project financing or partner deals, and reduces fixed interest burdens that could otherwise accelerate balance-sheet stress over the medium term.

Proprietary Immuno-oncology PlatformA diversified, next-generation immuno-oncology pipeline (CAR T, oncolytic viruses, iTANK) represents a durable strategic asset: multiple modality exposure increases probability of at least one clinical or partnership success and supports longer-term licensing or collaboration opportunities.

High Gross Profit When Revenue ExistedHistorical near-full pass-through gross profit implies the company’s direct-cost structure can deliver high margins on revenue. If clinical or partnered commercialization materializes, this scalable gross margin profile supports sustainable unit economics despite elevated R&D overheads.

Bears Say

Persistent Operating LossesMulti-year operating and net losses indicate the business is not self-sustaining; ongoing negative profitability will continue to erode equity, force outside financing or dilution, and constrain strategic options absent a material shift in revenue or successful partnering.

Weak Cash Generation / Cash BurnConsistently negative operating and free cash flow shows the company relies on external capital to fund operations. Persistent cash burn increases financing risk, can dilute existing shareholders, and complicates multi-quarter planning absent secured partnership or funding commitments.

Declining Equity & Revenue VolatilityMaterial equity decline from losses plus a revenue stream that fell to zero in 2025 signal weakening financial resilience and poor commercial visibility. This combination raises the probability of future financing, weakens lender/partner negotiating position, and increases medium-term execution risk.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.23 and its highest was €0.67 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €19.71M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 76 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 72,803,314 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.677%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.